Biochirp

ASOs with improved CNS delivery/activity 👇 #genetherapy #biotech #news #cns https://lnkd.in/gunU2fqE

Researchers have generated a nanoscale-resolution reconstruction of a millimeter-scale fragment of human cerebral cortex, giving an unprecedented view into the structural organization of brain tissue at the supracellular, cellular, and subcellular levels. 📄: https://scim.ag/71X

NEW BLOG: tried to make sense of the gene therapy theme in CV disease #genetherapy #heartfailure #cardiac #aav #lvv #biotech #substack #clinicaltrials

Day One Biopharmaceuticals receives FDA Approval for OJEMDA (tovorafenib) in relapsed/refractory pLGG: https://lnkd.in/gtxxaWZG #fda #fdaapproval #clinicaltrials #braincancer #oncology

RNA-editing drugs advance into clinical trials #genetherapy #rna #adar https://lnkd.in/gD6_heX4

Regeneron announced a new venture fund committing $100 million per year for the next five years into early stage cardiovascular/metabolic, blood cancers, oncology, ophthalmology and infectious disease technologies. #venturecapital #lifescience #oncology https://lnkd.in/gYrU3qhZ

Life Science investors Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW Investments, T. Rowe Price and Woodline Partners LP join on 160.5M Series C for Obsidian Therapeutics. Obsidian’s lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). #oncology #tils #celltherapy #venturecapital #lifescience https://lnkd.in/eExbpjBU

Korro Bio is one of the leading RNA medicine companies in the field, going head to head against Wave Life Sciences. But how will the future IP battle play out as ProQR Therapeutics holds key ADAR patents? #rna #geneediting #biotech #genetherapy

Carisma Therapeutics announced a 37% workforce reduction and pipeline prioritization: Company to prioritize CT-0525 as its anti-HER2 CAR-M product (monocyte product) candidate and will cease further development of CT-0508 (macrophage product) Cash and cash equivalents of $77.6 million as of December 31, 2023, combined with a restructuring of operations, including pausing development of CT-1119, expected to fund the Company into the third quarter of 2025 #biotech #drugdevelopment #celltherapy

We could not be more excited to announce this important milestone. Building a recognizable brand is often overlooked by fast-growing biotech companies. This is a big step forward for Octagon Therapeutics